CJC-1295 DAC (5mg) + Ipamorelin (5mg) Stack
Components: CJC-1295 DAC + Ipamorelin
A high-capacity GH secretagogue stack combining CJC-1295 DAC (5mg vial) and Ipamorelin (5mg vial). The larger CJC-1295 DAC vial provides 2.5–5 standard doses, suitable for extended 8–16 week cycles.
Stack Components
This stack uses 2 separate vials — each peptide is reconstituted independently.
| Peptide | Dose | Frequency | Timing | Route |
|---|---|---|---|---|
| CJC-1295 DAC Long-acting GHRH analogue; 6u20138 day half-life via albumin binding (DAC moiety); sustains elevated GH and IGF-1 throughout the week | 1000 mcg (1 mg) standard; up to 2000 mcg aggressive u2014 once weekly | Once weekly | Consistent day each week | SubQ |
| Ipamorelin Selective ghrelin receptor agonist; selective GH pulse stimulation without cortisol or ACTH elevation | 100 mcg (Weeks 1u20132) u2192 150 mcg (Weeks 3u20134) u2192 200 mcg (Weeks 5+) | Once daily | Before bed u2014 coincides with natural nocturnal GH release | SubQ |
Reconstitution Guide
Each peptide in this stack is a separate vial. Reconstitute them one at a time using the parameters below.
CJC-1295 DAC
SubQIpamorelin
SubQAlways use bacteriostatic water to reconstitute each vial. Draw from separate vials — do not mix in the same syringe unless your protocol specifies a shared injection.
Protocol Timeline
Full 8–16 weeks cycle breakdown.
CJC-1295 DAC: 1000 mcg (40 units, 0.40 mL) once weekly. Ipamorelin: 100 mcg (6 units) once daily before bed. 5mg vial at 2.5 mg/mL provides 2.5 standard (1 mg) doses u2014 plan accordingly.
CJC-1295 DAC: continue 1000 mcg once weekly. Ipamorelin: advance to 150 mcg (9 units) once daily. GH/IGF-1 axis fully established; early body composition improvements typically begin.
CJC-1295 DAC: continue 1000 mcg once weekly. Ipamorelin: advance to 200 mcg (12 units) once daily. Sustained complementary GH stimulation throughout the week.
The 5mg CJC-1295 DAC vial supports extension to 16 weeks at the 1 mg/week standard dose (5 doses total). Continue Ipamorelin at maintenance dose. Allow at least 4 weeks off after completing the cycle.
Synergy Notes
CJC-1295 DAC provides continuous background GHRH stimulation lasting 6–8 days per weekly injection. Ipamorelin adds daily selective GH pulses through the ghrelin receptor. The 5mg vial size provides 2.5 doses at the standard 2 mg/week aggressive dose or 5 doses at the 1 mg/week standard dose — offering flexibility for 8–16 week cycles without the need for frequent reordering. Ipamorelin's selectivity (no significant cortisol/ACTH elevation) makes it the preferred GHRP partner for extended cycles.
What to Expect
Weeks 1–3: Improved sleep depth and quality. Weeks 4–8: Progressive improvements in lean mass and body composition. Weeks 9–16: Continued anabolic and body composition benefits. Possible mild water retention in early weeks, resolving as the body adjusts.
Questions about CJC-1295 DAC (5mg) + Ipamorelin (5mg) Stack
At 2.5 mg/mL (2.0 mL BAC water), one 5mg vial provides 2.5 standard doses of 1 mg (1000 mcg) each, or 1.25 aggressive doses of 2 mg (2000 mcg) each.
At 200 mcg once daily for 12 weeks (84 days), total Ipamorelin needed is 16.8 mg u2014 approximately 4 vials of 5mg each.
They can be combined in one injection on the weekly CJC-1295 DAC day. On the other 6 days of the week, only Ipamorelin is injected (pre-sleep).
Research Use Disclaimer
This content is for educational purposes only and does not constitute medical advice. For research use only.